Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients
View/ Open
Access
info:eu-repo/semantics/embargoedAccessDate
2021Author
Peled, NirGillis, Roni
Kılıçkap, Saadettin
Froesch, Patrizia
Orlov, Sergei
Filippova, Elena
Demirci, Umut
Christopoulos, Petros
Çiçin, İrfan
Buğdaycı Basal, Fatma
Yılmaz, Cengiz
Fedor, Moiseenko
Korkmaz, Taner
Paydaş, Semra
Gautschi, Oliver
Zırtıloğlu, Alişan
Eralp, Yeşim
Yeşil Çınkır, Havva
Sezer, Ahmet
Erman, Mustafa
Tural, Deniz
Turna, Hande
Mazieres, Julien
Dudnik, Elizabeth
Reguart, Noemi
Camidge, David Ross
Ng, Terry L.
Çay Şenler, Filiz
Beypınar, İsmail
Yazılıtaş, Doğan
Demirkazık, Ahmet
Karaoğlu, Aziz
Okutur, Kerem
Coşkun, Hasan Şenol
Şendur, Mehmet Ali Nahit
Işıkdoğan, Abdurrahman
Çabuk, Devrim
Yumuk, Perran Fulden
Yıldız, İbrahim
Kaplan, Mehmet Ali
Özyılkan, Özgür
Öztop, İlhan
Ölmez, Ömer Fatih
Aydın, Kübra
Aydıner, Adnan
Meydan, Nezih
Grinberg, Roxana Denisa
Roisman, Laila C.
Metadata
Show full item recordCitation
Peled, N., Gillis, R., Kılıçkap, S., Froesch, P., Orlov, S., Filippova, E. ... Roisman, L. C. (2021). Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients. Journal of Thoracic Oncology içinde (S656-S656. ss.).Abstract
Introduction: Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1(+) is still pending. Here we present the largest real-world data of NSCLC patients harboring ALK/ROS1 rearrangements treated with lorlatinib.
WoS Q Kategorisi
Q1Source
Journal of Thoracic OncologyVolume
16Issue
3Collections
- Bildiri Koleksiyonu [516]
- WoS İndeksli Yayınlar Koleksiyonu [6696]